Doctor Aaron Kithcart

(United States of America)

Membership: ESC Professional Member

Follow

Contributor content

Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

Presentation

Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

ESC 365 is supported by

novartis

Explore sponsored resources